6th Cancer Cachexia Conference
|
Clinical Advances in Cancer Cachexia | |
---|---|
Session A: Outcome Measures for Cancer Cachexia Co-Chairs: |
|
8:10 am |
Introductory Remarks Denis C. Guttridge, PhD Jonathan D. Licht, MD Ray DuBois, MD, PhD Kelvin Lee, MD |
8:30 am | David Currow, MD University of Technology Sydney, Australia “What have we learnt from clinical trials in cancer cachexia?” |
9:00 am | Jann Arends, MD University of Freiburg, Germany “Clinical practice guidelines on cancer cachexia” |
9:30 am | Jorge Nieva, MD University of Southern California, USA “Karnofsky revisited – Measuring performance status in the digital age” |
10:00 am | Break |
Session B: Clinical Trial Results Co-Chairs: |
|
10:30 am | Marie Fallon, MD University of Edinburgh, UK “Phenotyping of patients in clinical trials of cancer cachexia” |
11:00 am | Tora Solheim, MD, PhD St. Olavs Hospital, Trondheim University Hospital, Norway “Why do we need a complex intervention in cancer cachexia?” |
11:30 am | Stein Kaasa, MD, PhD University of Oslo, Norway “Cancer cachexia classification anno 2022: A common system for research and clinical practice?” |
Selected Short Talks | |
12:00 pm | Ishan Roy, MD Northwestern University, USA “Six minute walk test improvement but not grip strength correlates with gains in functional independence in cancer patients with cachexia” |
12:15 pm | Rebekah Patton, PhD University of Edinburgh, UK “A prospective characterization of cancer cachexia in patients with incurable cancer” |
12:30 pm | Break |
Session C: Conversations with Patients and Caregivers Co-Chairs: |
|
1:30–2:30 pm |
Panelists: Richard Dunne, MD |
2:30-4:00 pm | Break |
Session 1 Keynote Address | |
Co-Chairs: |
|
4:00 pm | Kenneth C.H. Fearon Keynote Lectureship Bette J Caan, PhD Kaiser Permanente, USA "Muscle wasting in non-metastatic cancer: Advances in our understanding, assessment and treatment" |
Cutting Edge Science in Cancer Cachexia Junior investigators chosen from submitted abstracts |
|
5:00 pm | Miriam Ferrer Gonzalez – Cold Spring Harbor, USA “Early neutrophilia marked by aerobic glycolysis sustains host metabolism and delays cancer cachexia” |
5:05 pm | Gillian Gresham, PhD – Cedars-Sinai Medical Center, USA “Remote monitoring of biometric data and patient-reported outcomes in patients with cancer cachexia during the COVID-19 pandemic” |
5:10 pm | Michelle Law, PhD – Baylor College of Medicine, USA “Cardiac myocyte intrinsic contractility and calcium handling deficits underlie heart organ dysfunction in murine cancer cachexia” |
5:15 pm | Ja Young Kim-Muller, PhD – Pfizer Global, USA “GDF15 neutralization improves muscle function and physical performance in a mouse model of cancer cachexia” |
5:20 pm | Benjamin Pryce, PhD – Medical University of South Carolina, USA “Local inflammation in cancer cachexia derives from multiple cell populations in the muscle microenvironment under the control of NF-kB” |
5:25 pm | Yichi Zhang – University of Texas Southwestern, USA “Molecular mechanisms defining cancer cachexia-induced muscle atrophy” |
5:30-6:30 pm | Social Hour |
Session 2 Metabolic Dysfunction in Cancer Cachexia | |
---|---|
Co-Chairs: |
|
8:30 am | Pankaj K. Singh, PhD University of Nebraska Medical Center, USA "Molecular regulation of oxidative damage in skeletal muscle in pancreatic cancer" |
9:00 am | Stephan Herzig, PhD Helmholtz Diabetes and Cancer Center, Germany "Organ-specific metabolic programs in cancer cachexia" |
Selected Short Talks | |
9:30 am | Lykke Sylow, PhD University of Copenhagen, Denmark “AMPK protects against cancer-associated muscle mass loss and metabolic perturbations” |
9:45 am | Aneesha Dasgupta, PhD Mayo Clinic, USA “Anti-cachectic regular analysis reveals novel anti-tumorigenic mechanisms of 3-MA via the inhibition of Perp in pancreatic cancer” |
10:30 am | Break |
Session 3 Mechanisms of Skeletal Muscle Wasting: Myofiber | |
Co-Chairs: |
|
11:00 am | Paul Gregorevic, PhD University of Melbourne, Australia “Exploring and targeting new mechanisms implicated in muscle wasting associated with cancer cachexia” |
11:30 am | David Glass, MD Regeneron, USA “Overlap between mechanisms of Covid19-induced ARDS and cachexia” |
12:00 pm | Andrew Judge, PhD University of Florida, USA “Mechanisms of cachexia initiation” |
12:30 pm | Break |
1:30-4:00 pm | Poster Viewing |
Session 4 Nutrition Imbalance and Strategies in Cancer Cachexia | |
Co-Chairs: |
|
4:00 pm | Klaske van Norren, PhD Wageningen University, Netherlands "The gut brain axis in the cancer-related anorexia-cachexia syndrome" |
4:30 pm | Cristina Cintra Gomes Marcondes, PhD University of Campinas, Brazil "Nutrition as a coadjuvant therapy in cachexia preclinical models" |
Selected Short Talks | |
5:00 pm | Tor Erik Rusten, PhD University of Oslo, Norway "Autophagy mediates organ wasting and nutrient mobilization for tumor growth in Drosophila melanogaster" |
5:15 pm | Marc Beltrà, PhD University of Torino, Italy "Niacin supplement restores NAD+ levels and counteracts muscle wasting in cancer and chemotherapy-driven cachexia" |
5:30 pm | End of program day |
Session 5 Biological Variables in Cancer Cachexia | |
---|---|
Co-Chairs: |
|
8:30 am | Vickie Baracos, PhD University of Alberta, Canada "Sexual dimorphism in clinical cancer cachexia: fact or fiction?" |
9:00 am | James Carson, PhD University of Tennessee Health Science Center, USA “Understanding female systemic and skeletal muscle metabolic dysfunction with cancer cachexia and chemotherapy in mice” |
Selected Short Talks | |
9:30 am | Dario Coletti, PhD Sapienza University of Rome, Italy "Displaced myonuclei in cancer cachexia suggest altered innervation" |
9:45 am | Pauline Morigny, PhD Helmholtz Diabetes and Cancer Center, Germany "Association of circulating PLA2G7 levels with cancer cachexia and assessment of darpladib as a therapy" |
10:00 am | Break |
Session 6 Next Generation Researchers in Cancer Cachexia | |
Co-Chairs: To promote upcoming and young faculty researchers: Speakers chosen from submitted applications. |
|
10:30 am | Lindsey Anderson, PhD University of Washington, USA “Whole-body and adipose tissue metabolic phenotype in cancer patients” |
10:45 am | Shinpei Kawaoka, PhD Kyoto University, Japan “Remote solid cancers rewire hepatic nitrogen metabolism via host nicotinamide-N-methyltransferase” |
11:00 am | Young-Mee Kim, PhD University of Illinois at Chicago, USA “Downregulation of PGC1-alpha in the skeletal muscle endothelium mediates cancer cachexia by compromising vascular barrier integrity” |
11:15 am | Fabrizio Pin, PhD Indiana University School of Medicine, USA “Mitochondria-targeted agent MitoQ improves muscle atrophy, weakness and oxidative metabolism in C26 tumor-bearing mice” |
11:30 am | Joseph Rupert, PhD Indiana University School of Medicine, USA “Deletion of PKC-theta in mice with PDAC is associated with increased survival, increased in vivo muscle force production, decreased muscle wasting, and reduced expression of Pdk4 in skeletal muscle” |
11:45 am | Wouter van de Worp Maastricht University, Netherlands “Automated quantification of tumor volume and characterization of cachexia in a novel orthotopic lung cancer mouse model” |
12:00 pm | Break |
Session 7 Mechanisms of Muscle Wasting: Muscle Microenvironment | |
Co-Chairs: |
|
1:30 pm | Michael Rudnicki, PhD University of Ottawa, Canada "Molecular regulation of stem cell function" |
2:00 pm | Denis Guttridge, PhD Medical University of South Carolina, USA “The interplay between the inflammatory cascade and muscle atrophy in cancer cachexia” |
2:30 pm | Jerome Feige, PhD Nestle, Switzerland "Targeting muscle stem cells through nutrition in aging and cancer cachexia" |
3:00 pm | Break |
Session 8 Therapy-Induced Muscle Dysfunction and Wasting | |
Co-Chairs: |
|
3:30 pm | Andrea Bonetto, PhD Indiana University, USA "Novel insights into the mechanisms of chemotherapy-induced muscle wasting" |
4:00 pm | Chris Coss, PhD The Ohio State University, USA "Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans" |
Selected Short Talks | |
4:30 pm | Russell Hepple, PhD University of Florida, USA “Doxorubicin toxicity in skeletal muscle involves mitochondrial permeability transition” |
4:40 pm | Ashley Smuder, PhD University of Florida, USA "Mitochondrial dysfunction in chemotherapy-related myotoxicity" |
4:50 pm | Nicolas Collao University of Ottawa, Canada “Radiation therapy reduces skeletal muscle fibro-adipogenic progenitors and induces a profibrotic phenotype” |
5:00 pm | Closing Remarks |